Merkel Cell Carcinoma

Quick Answer

Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. It is highly FDG-avid, so FDG-PET/CT is recommended for staging and restaging (it frequently upstages disease and changes management), complemented by sentinel-lymph-node mapping for the clinically node-negative patient. Because MCC is neuroendocrine, a subset expresses somatostatin receptors (variable DOTATATE uptake), an emerging avenue. Advanced disease responds strikingly to immune-checkpoint inhibitors.

Definition

MCC is a rare, aggressive primary cutaneous neuroendocrine carcinoma, thought to arise from or share features with Merkel (mechanoreceptor) cells. It is strongly associated with the Merkel cell polyomavirus (MCPyV) and with UV exposure/immunosuppression.

Synonyms

Merkel cell carcinoma (MCC); cutaneous (primary) neuroendocrine carcinoma of the skin; trabecular carcinoma of the skin (historical).

Epidemiology

MCC predominantly affects older, fair-skinned, sun-exposed individuals and the immunosuppressed (transplant, HIV, hematologic malignancy). Incidence has risen. Roughly ~80% of cases are MCPyV-positive; the remainder are UV-signature-driven.

Etiology & Risk Factors

• Ultraviolet exposure (sun-exposed head/neck and extremities).
• Immunosuppression (organ transplant, HIV, CLL).
• Merkel cell polyomavirus (MCPyV) integration (virus-positive tumors).
• Advanced age.

Pathophysiology

Two biological routes converge on an aggressive neuroendocrine carcinoma: MCPyV integration with expression of viral T-antigens, or UV-mutagenesis (high tumor mutational burden, virus-negative). Both retain neuroendocrine differentiation (synaptophysin, chromogranin, INSM1) with a characteristic perinuclear dot-like CK20, and a subset express somatostatin receptors. MCC spreads early to regional nodes, with in-transit and distant metastases; the high mutational burden/viral antigens underlie its immunotherapy sensitivity.

Genetics & Molecular Biology

• MCPyV-positive: viral T-antigen-driven, relatively low mutational burden.
• Virus-negative: UV-signature, high mutational burden, RB1/TP53 alterations.
• Both express neuroendocrine markers and often PD-L1 — the basis for checkpoint-inhibitor benefit; variable SSTR expression enables DOTATATE imaging in a subset.

Histopathology

Small round blue cells with scant cytoplasm, high mitotic rate, and neuroendocrine markers; the CK20 perinuclear dot is characteristic (helping distinguish MCC from small-cell lung carcinoma metastasis, which is typically TTF-1-positive/CK20-negative).

Clinical Presentation

A rapidly growing, painless, firm, red-violaceous nodule on sun-exposed skin, summarized by the AEIOU features (Asymptomatic, Expanding rapidly, Immunosuppressed, Older than 50, UV-exposed/fair skin). Regional nodal disease is common at presentation.

Laboratory Findings

No routine serum marker for burden. MCPyV oncoprotein antibody (AMERK) titers can aid surveillance in seropositive patients. Tissue diagnosis with neuroendocrine + CK20 immunohistochemistry.

Imaging Findings by Modality

• FDG-PET/CT: the recommended whole-body staging/restaging tool — MCC is highly avid; PET frequently upstages and changes management.
• Sentinel-lymph-node lymphoscintigraphy: nodal staging in the clinically node-negative patient (as in melanoma).
• CT/MRI: anatomic staging and specific sites (brain if indicated).
• SSTR-PET (DOTATATE): variable uptake in a subset — emerging, not standard.

Radiopharmaceutical Uptake Mechanisms

FDG reflects the high glucose metabolism of this aggressive carcinoma (reliably avid — the basis for PET staging). DOTATATE binds SSTR2 where expressed (variable), the rationale for occasional SSTR imaging and investigational PRRT. Sentinel-node radiocolloids map lymphatic drainage physically.

Typical PET Tracers

Typical SPECT Tracers

• Sentinel-node lymphoscintigraphy (Tc-99m-sulfur colloid / tilmanocept ± SPECT/CT).

Therapy Indications

• Localized: wide excision + sentinel-node biopsy; MCC is radiosensitive (adjuvant/definitive radiotherapy is important).
• Advanced/metastatic: immune-checkpoint inhibitors (avelumab, pembrolizumab) — highly effective and now first-line for many.
• Investigational: PRRT (¹⁷⁷Lu-DOTATATE) for SSTR-avid, immunotherapy-refractory disease.

Theranostics

MCC's potential theranostic is SSTR-directed in the subset that expresses somatostatin receptors (DOTATATE imaging → PRRT), still investigational. The mainstay for advanced disease is immunotherapy, and nuclear medicine's core value is FDG staging and sentinel-node mapping.

Differential Diagnosis

• Small-cell lung carcinoma metastasis to skin (TTF-1+/CK20−, vs MCC CK20 dot).
• Cutaneous lymphoma, basal/squamous cell carcinoma, amelanotic melanoma, and other small-blue-cell tumors.
• Benign inflammatory nodules (rapid growth and AEIOU features raise suspicion).

Reporting Checklist

• FDG staging: report nodal, in-transit, and distant disease; note frequent upstaging.
• Sentinel node: drainage basins and node number (SPECT/CT).
• If DOTATATE performed, report SSTR avidity (emerging/therapy-relevant).
• Correlate with the primary site and MCPyV status where known.

Prognosis

MCC is aggressive and stage-dependent, with a substantial risk of nodal and distant spread; accurate FDG staging matters because upstaging changes therapy. Immune-checkpoint inhibitors have markedly improved advanced-disease outcomes, and radiotherapy provides strong local/regional control.

Board Pearls

MCC is highly FDG-avid, so FDG-PET/CT is recommended for staging/restaging and frequently upstages disease and changes management; sentinel-lymph-node mapping stages the clinically node-negative patient (as in melanoma).

MCC is a cutaneous neuroendocrine carcinoma (CK20 perinuclear dot; synaptophysin/INSM1) linked to Merkel cell polyomavirus and UV/immunosuppression — and a subset expresses SSTR (variable DOTATATE uptake), an emerging imaging/PRRT avenue.

Advanced MCC responds strikingly to immune-checkpoint inhibitors (avelumab, pembrolizumab), and it is radiosensitive. The CK20-dot / TTF-1-negative phenotype distinguishes it from small-cell lung carcinoma metastasis; investigational ¹⁷⁷Lu-DOTATATE PRRT is being explored for SSTR-avid, immunotherapy-refractory disease.

Related Pages

• Tracers: FDG, DOTATATE PET agents; related disease: Neuroendocrine tumors (SSTR biology), melanoma (sentinel node / skin-cancer staging).
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• An AEIOU clinical-feature graphic.
• A dual-pathway biology diagram (MCPyV vs UV-mutagenesis → neuroendocrine carcinoma).
• An FDG staging upstaging before/after schematic.

Common Pitfalls

• On checkpoint immunotherapy, immune-related inflammation (sarcoid-like nodes, immune-organ uptake) and pseudoprogression mimic true progression — as in melanoma, confirm equivocal change before calling failure.
• MCC is radiosensitive and often irradiated, so post-radiotherapy inflammatory uptake at the primary or nodal bed can simulate residual or recurrent disease — account for treatment timing.
• DOTATATE uptake is variable or absent, so SSTR-PET cannot be relied on for staging (FDG remains the staging tracer) and a negative DOTATATE study does not exclude MCC.
• Head/neck sentinel-node mapping is prone to injection-site shine-through and ambiguous drainage — SPECT/CT clarifies the true first-echelon node.

Self-Check (Board-Style)